Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 24

Related Articles by Review for PubMed (Select 19998512)

1.

Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor.

Kaemmerer D, Prasad V, Daffner W, Hörsch D, Klöppel G, Hommann M, Baum RP.

World J Gastroenterol. 2009 Dec 14;15(46):5867-70.

2.

Peptide-receptor radionuclide therapy for endocrine tumors.

van Essen M, Krenning EP, Kam BL, de Jong M, Valkema R, Kwekkeboom DJ.

Nat Rev Endocrinol. 2009 Jul;5(7):382-93. doi: 10.1038/nrendo.2009.105. Epub 2009 Jun 2. Review.

PMID:
19488074
3.

Peptide receptor radionuclide therapy for advanced neuroendocrine tumors.

Bodei L, Cremonesi M, Kidd M, Grana CM, Severi S, Modlin IM, Paganelli G.

Thorac Surg Clin. 2014 Aug;24(3):333-49. doi: 10.1016/j.thorsurg.2014.04.005. Epub 2014 Jun 9. Review. Erratum in: Thorac Surg Clin. 2014 Nov;24(4):xv.

PMID:
25065935
4.

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs.

Kwekkeboom DJ, Krenning EP, Lebtahi R, Komminoth P, Kos-Kudła B, de Herder WW, Plöckinger U; Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society.

Neuroendocrinology. 2009;90(2):220-6. doi: 10.1159/000225951. Epub 2009 Aug 28.

PMID:
19713714
5.

Treatment of gastroenteropancreatic neuroendocrine tumors with peptide receptor radionuclide therapy.

van Vliet EI, Teunissen JJ, Kam BL, de Jong M, Krenning EP, Kwekkeboom DJ.

Neuroendocrinology. 2013;97(1):74-85. doi: 10.1159/000335018. Epub 2012 Jan 10. Review.

PMID:
22237390
6.

Update: improvement strategies for peptide receptor scintigraphy and radionuclide therapy.

de Visser M, Verwijnen SM, de Jong M.

Cancer Biother Radiopharm. 2008 Apr;23(2):137-57. doi: 10.1089/cbr.2007.0435. Review.

PMID:
18454684
7.

Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors.

Kwekkeboom DJ, de Herder WW, Krenning EP.

Endocrinol Metab Clin North Am. 2011 Mar;40(1):173-85, ix. doi: 10.1016/j.ecl.2010.12.003. Review.

PMID:
21349418
8.

Pancreatic neuroendocrine tumors.

Muniraj T, Vignesh S, Shetty S, Thiruvengadam S, Aslanian HR.

Dis Mon. 2013 Jan;59(1):5-19. doi: 10.1016/j.disamonth.2012.10.002. Review. No abstract available.

PMID:
23312533
9.

GEPNETs update: Radionuclide therapy in neuroendocrine tumors.

van der Zwan WA, Bodei L, Mueller-Brand J, de Herder WW, Kvols LK, Kwekkeboom DJ.

Eur J Endocrinol. 2015 Jan;172(1):R1-8. doi: 10.1530/EJE-14-0488. Epub 2014 Aug 12. Review.

10.

Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.

Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, O'dorisio TM, Valkema R, Bodei L, Chinol M, Maecke HR, Krenning EP.

J Nucl Med. 2005 Jan;46 Suppl 1:62S-6S. Review.

11.

Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages.

Gillen S, Schuster T, Meyer Zum Büschenfelde C, Friess H, Kleeff J.

PLoS Med. 2010 Apr 20;7(4):e1000267. doi: 10.1371/journal.pmed.1000267. Review.

12.

Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.

De Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WA, Bakker WH, Smith C, Pauwels S, Krenning EP.

Semin Nucl Med. 2002 Apr;32(2):133-40. Review.

PMID:
11965608
13.

Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues.

Bodei L, Pepe G, Paganelli G.

Eur Rev Med Pharmacol Sci. 2010 Apr;14(4):347-51. Review.

PMID:
20496546
14.

[Liver trasplantation for the treatment of non-resectable metastases of neuroendocrine tumors: first report in Argentina].

Quiñonez E, Capitanich P, Anders M, Fernández JL, Serafini V, Viola L, Mastai R, McCormack L.

Acta Gastroenterol Latinoam. 2011 Sep;41(3):242-6. Review. Spanish.

PMID:
22233004
15.

Beta-emitting radionuclides for peptide receptor radionuclide therapy.

Parus JL, Mikolajczak R.

Curr Top Med Chem. 2012;12(23):2686-93. Review.

PMID:
23339764
16.

Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.

Kwekkeboom DJ, Kam BL, van Essen M, Teunissen JJ, van Eijck CH, Valkema R, de Jong M, de Herder WW, Krenning EP.

Endocr Relat Cancer. 2010 Jan 29;17(1):R53-73. doi: 10.1677/ERC-09-0078. Print 2010 Mar. Review.

17.

Surgical management of pancreatic endocrine tumors.

Fendrich V, Waldmann J, Bartsch DK, Langer P.

Nat Rev Clin Oncol. 2009 Jul;6(7):419-28. doi: 10.1038/nrclinonc.2009.82. Epub 2009 Jun 9. Review.

PMID:
19506584
18.

Peptide receptor radionuclide therapy with somatostatin analogues in neuroendocrine tumors.

Giovacchini G, Nicolas G, Forrer F.

Anticancer Agents Med Chem. 2012 Jun;12(5):526-42. Review.

PMID:
22292758
19.

Surgical management of pancreatic neuroendocrine tumors.

Kimura W, Tezuka K, Hirai I.

Surg Today. 2011 Oct;41(10):1332-43. doi: 10.1007/s00595-011-4547-6. Epub 2011 Sep 16. Review.

PMID:
21922354
20.

Aggressive surgical resection in the management of pancreatic neuroendocrine tumors: when is it indicated?

Hodul PJ, Strosberg JR, Kvols LK.

Cancer Control. 2008 Oct;15(4):314-21. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk